Wells Fargo Raises Kyverna Therapeutics (KYTX) PT to $27 on Confidence in KYV-101 Stiff Person Syndrome Trial Readout

Kyverna Therapeutics Inc. (NASDAQ:KYTX) is one of the best young stocks with huge upside potential. On October 8, Wells Fargo ...
Nasdaq

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

EMERYVILLE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with ...
Nasdaq

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

EMERYVILLE, Calif., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with ...

Nasdaq Earnings: What To Look For From NDAQ

Global exchange operator Nasdaq (NASDAQ:NDAQ) will be reporting earnings this Tuesday before market open. Here’s what to ...
Nasdaq

Cabral Gold Announces Filing of NI 43-101 Technical Report for Updated Prefeasibility Study on the Gold-in-Oxide Starter Operation at the Cuiú Cuiú Gold Project, Brazil

Vancouver, British Columbia--(Newsfile Corp. - September 11, 2025) - Cabral Gold Inc. (TSXV: CBR) (OTCQB: CBGZF) ("Cabral" or the "Company") is pleased to announce that it has filed a National ...
Nasdaq

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin ...